Copenhagen, Denmark
Onsite/Online

ESTRO 2022

Session Item

Saturday
May 07
10:30 - 11:30
Auditorium 12
Normal tissue radiobiology
Brita Singers Sørensen, Denmark;
Ludwig Dubois, The Netherlands
1210
Proffered Papers
Radiobiology
11:10 - 11:20
Preclinical assessment of protective role of anti-androgens in reducing RT-induced bladder toxicity
Riccardo Vago, Italy
OC-0098

Abstract

Preclinical assessment of protective role of anti-androgens in reducing RT-induced bladder toxicity
Authors:

Riccardo Vago1,2, Stefania Zuppone3, Giorgia Colciago3, Giuseppe Fallara4, Andrea Gebbia5, Nadia Di Muzio6, Antonello Spinelli7, Claudio Fiorino5, Cesare Cozzarini6

1 IRCCS San Raffaele Scientific Institute, Urological Research Institute - Division of Experimental Oncology, Milan, Italy; 2IRCCS San Raffaele Scientific Institute, Università Vita-Salute San Raffaele, Milan, Italy; 3IRCCS San Raffaele Scientific Institute, Urological Research Institute - Division of Experimental Oncology, Milan, Italy; 4IRCCS San Raffaele Scientific Institute, Urology, Milan, Italy; 5IRCCS San Raffaele Scientific Institute, Medical Physics, Milan, Italy; 6IRCCS San Raffaele Scientific Institute, Radiotherapy, Milan, Italy; 7IRCCS San Raffaele Scientific Institute, Experimental Imaging Centre, Milan, Italy

Show Affiliations
Purpose or Objective

Radiation-induced cystitis (RC) may arise when pelvic tumors, such as prostate cancer, are treated with radiotherapy (RT). The modeling of RT-induced urinary toxicity represents a complex topic, which is attracting increasing interest in radiotherapy. A thorough understanding of the mechanisms underlying RC is still largely lacking, and in vivo preclinical research has a decisive role in improving the knowledge concerning the causes and, hence, the possible solutions in order to at least limit its clinical impact.

To resemble this condition, we set up a rat animal model, which allowed us to follow the radiation-cystitis development over time. 

Material and Methods

We employed a range of techniques to monitor the RC cystitis, i.e. ultrasound imaging system, used to measure the bladder wall thickness, cystometry, to assess the bladder compliance and immunohistochemistry (IHC) to investigate structural alteration, vascularization and fibrosis. The anti-androgen Degarelix was used to mitigate the inflammatory radiation effect since experimental models previously developed at our Institute had highlighted both the anti-inflammatory and antifibrotic effects of an antiandrogen in a rat model of bladder damage.

Results

Radiation induced bladder wall thickness increased over time and it was especially relevant after high doses RT (Figure 1) in the range of 35-40 Gy (single fraction). We then evaluated the RT-induced functional impairment of bladder compliance by monitoring the urodynamic parameters (Figure 2): at late time points (6-8 months), when fibrosis developed and the bladder capacity was reduced, a progressive reduction of micturition volume and a parallel increase of micturition events over time after RT were observed. In addition, preliminary structural assessment performed to confirm the observed functional impairment, revealed an increased vascularization (increased amount of CD31 positive vessels) and fibrosis (increased collagen I deposition). The Degarelix pretreatment prevented both the radiation-induced impairment of urodynamic parameters and structural alteration. Specifically, it increased the mean volume voided per micturition, the micturition interval and reduced the frequency, when compared to the same parameters observed in the RT-only treated animals. Moreover, it counteracted the neovascularization and the fibrosis processes.

Conclusion

Overall our data demonstrated that it is possible to set up and optimize a rat model of RC, resembling the disease in human beings, which allows to monitor its onset and development. The pretreatment of the animals with Degarelix thwarted the radiation-induced functional and structural alteration of the bladder, highlighting the potential of this approach to be exported to patients.

Figure 1


Figure 2